PF-04634817 SUCCINATE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H36F3N5O3.C4H6O4
Molecular Weight	629.6683
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CCC(O)=O.CO[C@@H]1COCC[C@@H]1N[C@@H]2CC[C@](C2)(C(C)C)C(=O)N3C[C@@H]4C[C@H]3CN4C5=NC=NC(=C5)C(F)(F)F

InChI

InChIKey=WRPPUEHVLSHXJG-HTQYHTRRSA-N

InChI=1S/C25H36F3N5O3.C4H6O4/c1-15(2)24(6-4-16(10-24)31-19-5-7-36-13-20(19)35-3)23(34)33-12-17-8-18(33)11-32(17)22-9-21(25(26,27)28)29-14-30-22;5-3(6)1-2-4(7)8/h9,14-20,31H,4-8,10-13H2,1-3H3;1-2H2,(H,5,6)(H,7,8)/t16-,17+,18+,19+,20-,24+;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C25H36F3N5O3
Molecular Weight	511.5802
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C4H6O4
Molecular Weight	118.088
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30450458 | https://www.ncbi.nlm.nih.gov/pubmed/29847672 | https://adisinsight.springer.com/drugs/800032291

PF-04634817 is a small molecule chemokine CCR2 and CCR5 receptor dual antagonist. Treatment with PF-04634817 was associated with a modest improvement in best-corrected visual acuity, which was inferior to intravitreal ranibizumab. Analysis of the primary endpoint, Urine Albumin-to-Creatinine Ratio, indicated a modest effect of PF-04634817 in reducing albuminuria in subjects with type 2 diabetes who received angiotensin receptor blocker therapy after 12 weeks of treatment. Despite the tolerable safety profile shown by PF-04634817, clinical development was discontinued in light of the modest efficacy observed.

Originator

Approval Year

PubMed

Title	Date	PubMed
Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy.	2018-11	30450458
A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema.	2018-05-01	29847672

Sample Use Guides

In Vivo Use Guide

200 mg once daily

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:57:27 GMT 2025` Edited by `admin` on `Mon Mar 31 19:57:27 GMT 2025`
Record UNII	FMG601PUW3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PF-04634817 SUCCINATE

Preferred Name

English

Code System Code Type Description

FDA UNII

FMG601PUW3

Created by admin on Mon Mar 31 19:57:27 GMT 2025 , Edited by admin on Mon Mar 31 19:57:27 GMT 2025

PRIMARY

PUBCHEM

121596583